Collateral damage: necroptosis in the development of lung injury

Cell death is increasingly recognized as a driving factor in the development of acute lung injury. Necroptosis, an immunogenic regulated cell death program important in innate immunity, has been implicated in the development of lung injury in a diverse range of conditions. Characterized by lytic cel...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Lung cellular and molecular physiology 2020-02, Vol.318 (2), p.L215-L225
Main Authors: Faust, Hilary, Mangalmurti, Nilam S
Format: Article
Language:English
Subjects:
Animal models
Animals
Apoptosis
Cell death
Disease Models, Animal
Humans
Immunogenicity
Inflammation
Injuries
Innate immunity
Lung Injury - microbiology
Lung Injury - pathology
Lung Injury - virology
Lungs
Models, Biological
Mortality
Necroptosis
Nitric oxide
Pathogenesis
Respiratory Tract Infections - complications
Respiratory Tract Infections - microbiology
Respiratory Tract Infections - virology
Review
Sepsis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell death is increasingly recognized as a driving factor in the development of acute lung injury. Necroptosis, an immunogenic regulated cell death program important in innate immunity, has been implicated in the development of lung injury in a diverse range of conditions. Characterized by lytic cell death and consequent extracellular release of endogenous inflammatory mediators, necroptosis can be both beneficial and deleterious to the host, depending on the context. Here, we review recent investigations linking necroptosis and the development of experimental lung injury. We assess the consequences of necroptosis during bacterial pneumonia, viral infection, sepsis, and sterile injury, highlighting increasing evidence from in vitro studies, animal models, and clinical studies that implicates necroptosis in the pathogenesis of ARDS. Lastly, we highlight current challenges in translating laboratory findings to the bedside.
ISSN:1040-0605
1522-1504
DOI:10.1152/AJPLUNG.00065.2019